Delphine Davan 🌎

Scientist, biz woman, mother, pet lover, outdoor addict & other adventures in 3 countries 🇫🇷~🇺🇸~🇨🇦

[Medicenna Therapeutics @Medicenna1]

Last June, our lead asset (MDNA55 or bizaxofusp) was featured on the cover page of #NeuroOncologyJournal. In this Phase 2b study in patients with rec. #glioblastoma, MDNA55 has doubled the mOS compared to SOC. All details in this #publication: https://t.co/Gu0qAce3IB

[Medicenna Therapeutics @Medicenna1]

#TBT to our clinical update on the ABILITY study in patients with advanced solid tumors. MDNA11 demonstrated an excellent #SafetyProfile across all cohorts and early signs of response: #PartialResponse in a patient with pancreatic cancer. See more here: https://t.co/53dPXNtsTY

[Medicenna Therapeutics @Medicenna1]

This Monday, we will present the preclinical results of our dual-functioning MDNA223 BiSKIT at the @AACR Special Conference in #CancerResearch: Tumor Immunology and #Immunotherapy. Learn about our MDNA BiSKIT program here: https://t.co/apYWmMgkQG

[Delphine Davan 🌎 @delphinedavan]

In Ph1 trial, @Medicenna1 MDNA11 #monotherapy was well tolerated across all cohorts and has shown promising therapeutic activity in patients who have progressed on multiple prior anti-#cancer therapies including a patient with a particularly aggressive form of #PancreaticCancer.

[Medicenna Therapeutics @Medicenna1]

Single-agent activity and durable #tumor control: #MDNA11 shows tumor control in 37% of patients. #MDNA11 demonstrated partial response in a patient with a highly aggressive tumor type.

For more updates, click the link https://t.co/dXJWayaKtG

[Medicenna Therapeutics @Medicenna1]

Single-agent activity and durable #tumor control: #MDNA11 shows tumor control in 37% of patients. #MDNA11 demonstrated partial response in a patient with a highly aggressive tumor type.

For more updates, click the link https://t.co/dXJWayaKtG

[Delphine Davan 🌎 @delphinedavan]

As macroeconomic trends continue to squeeze investment in #biotech companies, #AI-driven companies clearly have a prominent position in the #pharmaceutical industry. We are now starting to see impact in the AI-driven biotech compa…https://t.co/PPbdFXuWvB https://t.co/yG6zD4HK21

[Delphine Davan 🌎 @delphinedavan]

Forget about #DesignThinking. AI requires a different skill, #EmergentThinking: generating ideas for innovation without fully understanding the problem that needs to be solved.

#ChatGPT is an unprecedented technology that has pote…https://t.co/B9nsTryJjs https://t.co/anoWnY9Zp6

[Delphine Davan 🌎 @delphinedavan]

Viens réseauter avec les professionnels de la #Communication et du #Marketing de la #CapitaleNationale ce jeudi soir en terrasse. Notre comité événement a commandé une belle température pour l'occasion ! https://t.co/qtWBBpQvRj

[Delphine Davan 🌎 @delphinedavan]

Mobilisation locale pour reprendre les installations de Medicago et faire de la @ville_de_quebec un pôle de recherche biopharmaceutique.

#biotech #biopharma https://t.co/MymZxQyxVP

[Delphine Davan 🌎 @delphinedavan]

The use of #AI in #oncology is rapidly increasing, and it has the potential to revolutionize #cancer diagnosis, treatment, and research. #DeepLearning models can also help clinicians predict the future development of cancer and som…https://t.co/qcaOycaDGD https://t.co/TjtlUt5iNo

[Delphine Davan 🌎 @delphinedavan]

Jour 2 à EFFERVESCENCE MTL où je suis ravie de représenter l'Agence IMPAKT Scientifik Inc., une entreprise québécoise spécialisée dans la communication scientifique ! Venez me rencontrer pour en savoir plus.! https://t.co/5Fi77W9Y15

[Delphine Davan 🌎 @delphinedavan]

Création d’un pôle d’innovation dédié aux #SciencesDeLaVie et de la #SantéDurable sur les installations de Medicago à Québec! When life gives you lemons, make lemonade!

#innovation Québec VITAE #VilleDeQuébec https://t.co/AzxfE0fEWK

[Delphine Davan 🌎 @delphinedavan]

Data presented today at the American Association of Cancer Research show that treatment with our lead #CancerVaccine (MVP-S) elicited a robust immune response against #OvarianCancer cells. Experiments demonstrate that T cells are able to migrate into tumo…https://t.co/SNPasvyc2X

[Delphine Davan 🌎 @delphinedavan]

The #biotech industry has always experienced the full throes of the business cycle, and this time is no different. Many of us believe the worst carnage in the #PublicMarkets is now behind us, so hopefully we can start the healthy p…https://t.co/6RezBml5yv https://t.co/8xaygZqrnQ

[Delphine Davan 🌎 @delphinedavan]

Pensez-vous être suffisamment outillé pour gérer une crise lorsqu'elle se présentera ? Peut-on être trop préparé ? (demandez aux pompiers). RDV le 25 avril. https://t.co/Yi9lmOiJi6

[Delphine Davan 🌎 @delphinedavan]

When antigens are delivered the right way to the immune system, it generates a targeted response that leads to clinical benefit with limited adverse events. MVP-S is IMV's first DPX-enabled #cancervaccine and has shown durable clinical benefit in several…https://t.co/yO94AuTspv

[Delphine Davan 🌎 @delphinedavan]

Le gouvernement du #Québec renforce son budget dédié à l'innovation en #sciencesdelavie. Une bonne nouvelle pour le secteur qui traverse actuellement une période difficile. https://t.co/TrB9rJ1r2c

[Delphine Davan 🌎 @delphinedavan]

@AirCanada any chance we get direct flights between BOS and YQB (Quebec) soon? I'm so fed up connecting in Montreal, or worse, Toronto... I cannot believe I'm the only one who flights to Boston regularly.

[IMV Inc. @imv_inc]

In June, we join @CancerResearch in celebrating 10 years of Cancer Immunotherapy Month! #Immunotherapy has the potential to bring targeted, long-lasting therapies to #cancer patients. Get involved with @CancerResearch here: https://t.co/eVHHq87JvX #Immune2Cancer

[Delphine Davan 🌎 @delphinedavan]

Future RI governor @helena_foulkes talking about aligning strategy on corporate purpose. She's a cancer survivor and was head of IR when @cvspharmacy removed tobacco from their stores. 👏🏻 #niri2022